Efficacy and safety of insulin glargine 300 U/ml versus glargine 100 U/ml in East Asian population with type 2 diabetes: a patient-level meta-analysis of phase 3 studies

被引：0
|
作者：
Ji, L. [1 ]
Bi, Y. [2 ]
Ye, S. [3 ]
Huang, Y. [4 ]
Zhang, X. [4 ]
Shang, S. [4 ]
Cui, N. [4 ]
机构：
[1] Peking Univ Peoples Hosp, Beijing, Peoples R China
[2] Nanjing Univ, Sch Med, Drum Tower Hosp, Nanjing, Peoples R China
[3] Univ Sci & Technol China, Affiliated Hosp 1, Hefei, Peoples R China
[4] Sanofi, Shanghai, Peoples R China
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
687
引用
收藏
页码：S331 / S332
页数：2
相关论文
共 50 条
  • [41] Insulin glargine 300 U/ml versus Insulin degludec 100 U/ml Direct Comparison of long-acting Insulins
    Stiefelhagen, Peter
    [J]. AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2019, 12 (01): : 38 - 38
  • [42] A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus
    Woo, Vincent C.
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (08) : S12 - S33
  • [43] Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
    Owens, David R.
    Traylor, Louise
    Mullins, Peter
    Landgraf, Wolfgang
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 124 : 57 - 65
  • [44] Is hypoglycaemia a modifiable patient risk in type 2 diabetes: A pooled analysis of insulin glargine 300 U/mL (Gla-300) vs 100U/mL (Gla-100) trials?
    Zhang, Q.
    Rosenstock, J.
    Gerrits, C.
    Liao, L.
    Chew, P.
    [J]. DIABETOLOGIA, 2015, 58 : S472 - S472
  • [45] Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3
    Bonadonna, Riccardo C.
    Yale, Jean-Francois
    Brulle-Wohlhueter, Claire
    Boelle-Le Corfec, Emmanuelle
    Choudhary, Pratik
    Bailey, Timothy S.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 715 - 719
  • [46] Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
    de Galan, Bastiaan E.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 2097 - 2106
  • [47] Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
    Takahisa Hirose
    Ching-Chu Chen
    Kyu Jeung Ahn
    Jacek Kiljański
    [J]. Diabetes Therapy, 2019, 10 : 805 - 833
  • [48] An Exploratory Study to Evaluate the Glycemic Variability by Continuous Glucose Monitoring (CGM) with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Patients with Type 2 Diabetes
    Franco, Denise R.
    Visconti, Guilherme D.
    Feder, Cecilia
    Baptista, Juliana
    Vianna, Andre G.
    Guimaraes, Mariana T.
    Souza, Flavia V.
    Tagata, Luciana A.
    Eliaschewitz, Freddy
    [J]. DIABETES, 2020, 69
  • [49] Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
    Maffeis, Claudio
    Rabbone, Ivana
    [J]. PEDIATRIC DRUGS, 2022, 24 (05) : 499 - 512
  • [50] New insulin glargine 300U/ml (Gla-300): glycaemic control and hypoglycaemia in insulin-naive people with Type 2 diabetes compared with glargine 100U/ml (Gla-100)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    [J]. DIABETIC MEDICINE, 2015, 32 : 78 - 78
12345